Delcath Systems CEO fired, board considers options after FDA rejection
This article was originally published in Scrip
Delcath Systems booted its CEO and the company’s board is reviewing options after the US FDA handed the drug and device maker a widely expected rejection for a cancer therapy.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.